Haematology and neurology

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 78, Issue 4, 2007, Pages 334-341

  Austin, Steven ^b   Cohen, Hannah ^c   Losseff, Nick ^a  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBIN; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 9; CORTICOSTEROID; CYCLOSPORIN A; DANAPAROID; HEPARINOID; IMMUNOSUPPRESSIVE AGENT; PROTEIN C; PROTEIN S; RITUXIMAB; THROMBIN INHIBITOR; VON WILLEBRAND FACTOR;

ANTIPHOSPHOLIPID SYNDROME; ARTERY THROMBOSIS; BLOOD TRANSFUSION; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; HYPERCOAGULABILITY; MULTIPLE MYELOMA; NEUROPATHY; PARADOXICAL EMBOLISM; PARAPROTEINEMIA; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SICKLE CELL ANEMIA; THROMBOPHILIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; VENOUS THROMBOEMBOLISM; WALDENSTROEM MACROGLOBULINEMIA; HEMATOLOGIC DISEASE; NEUROLOGIC DISEASE; NEUROLOGY; PATHOLOGY;

HEMATOLOGIC DISEASES; HUMANS; NERVOUS SYSTEM DISEASES; NEUROLOGY;

EID: 33947713917     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp.2006.092023     Document Type: Review

References (47)

1. Silverstein MD, Heit JA, Mohr DN, et al. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 1998;158:585-93.
2. Rosendaal FR. Venous thrombosis: a multicausal disease. Lancet 1999;353:1167-73.
3. van der Meer FJ, Koster T, Vandenbroucke JP, et al. The Leiden Thrombophilia Study (LETS). Thromb Haemost 1997;78:631-5.
4. Cushman M, Tsai AW, White RH, et al. Deep vein thrombosis and pulmonary embolism in two cohorts: the longitudinal investigation of thromboembolism etiology. Am J Med 2004;117:19-25.
5. Cushman M. Inherited risk factors for venous thrombosis. Hematology (Am Soc Hematol Educ Program) 2005:452-7.
6. Crowther MA, Kelton JG. Congenital thrombophilic states associated with venous thrombosis: a qualitative overview and proposed classification system. Ann Intern Med 2003;138:128-34.
7. Hansson PO, Sorbo J, Eriksson H. Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors. Arch Intern Med 2000;160:769-74.
8. van der Meer FJ, Koster T, Vandenbroucke JP, et al. The Leiden Thrombophilia Study (LETS). Thromb Haemost 1997;78:631-5.
9. Christiansen SC, Cannegieter SC, Koster T, et al. Thrombophilia, clinical factors, and recurrent venous thrombotic events. JAMA 2005;293:2352-61.
10. Baglin T, Luddington R, Brown K, et al. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. Lancet 2003;362:523-6.
11. Baglin TP, Keeling DM, Watson HG. Guidelines on oral anticoagulation (warfarin): third edition - 2005 update. Br J Haematol 2006;132:277-85.
12. Einhaupl KM, Villringer A, Meister W, et al. Heparin treatment in sinus venous thrombosis. Lancet 1991;338:597-600.
13. De Bruijn SF, Stam J. Randomized, placebo-controlled trial of anticoagulant treatment with low-molecular-weight heparin for cerebral sinus thrombosis. Stroke 1999;30:484-8.
14. Kenet G, Sadetzki S, Murad H, et al. Factor V Leiden and antiphospholipid antibodies are significant risk factors for ischemic stroke in children. Stroke 2000;31:1283-8.
15. Voetsch B, Damasceno BP, Camargo EC, et al. Inherited thrombophilia as a risk factor for the development of ischemic stroke in young adults. Thromb Haemost 2000;83:229-33.
16. De SV, Chiusolo P, Paciaroni K, et al. Prothrombin G20210A mutant genotype is a risk factor for cerebrovascular ischemic disease in young patients. Blood 1998;91:3562-5.
17. Furie KL, Kelly PJ. Homocyst(e)ine and stroke. Semin Neurol 2006;26:24-32.
18. Voetsch B, Damasceno BP, Camargo EC, et al. Inherited thrombophilia as a risk factor for the development of ischemic stroke in young adults. Thromb Haemost 2000;83:229-33.
19. Karttunen V, Hiltunen L, Rasi V, et al. Leiden and prothrombin gene mutation may predispose to paradoxical embolism in subjects with patent foramen ovale. Blood Coagul Fibrinolysis 2003;14:261- 8.
20. Lichy C, Reuner KH, Buggle F, et al. Prothrombin G20210A mutation, but not factor V Leiden, is a risk factor in patients with persistent foramen ovale and otherwise unexplained cerebral ischemia. Cerebrovasc Dis 2003;16:83-7.
21. Cramer SC, Rordorf G, Maki JH, et al. Increased pelvic vein thrombi in cryptogenic stroke: results of the Paradoxical Emboli from Large Veins in Ischemic Stroke (PELVIS) study. Stroke 2004;35:46-50.
22. Herity NA, Dalzell GW. Venous thrombosis causing arterial embolization to the same limb through a patent foramen ovale. Clin Cardiol 1997;20:893-6.
23. Turiel M, Muzzupappa S, Gottardi B, et al. Evaluation of cardiac abnormalities and embolic sources in primary antiphospholipid syndrome by transesophageal echocardiography. Lupus 2000;9:406-12.
24. Sanna G, Bertolaccini ML, Hughes GR. Hughes syndrome, the antiphospholipid syndrome: a new chapter in neurology. Ann N Y Acad Sci 2005;1051:465-86
25. Lampropoulos CE, Hughes GR. The antiphospholipid (Hughes') syndrome: changing the face of neurology. Eur J Intern Med 2004;15:147-50.
26. van Goor MP, Alblas CL, Leebeek FW, et al. Do antiphospholipid antibodies increase the long-term risk of thrombotic complications in young patients with a recent TIA or ischemic stroke? Acta Neurol Scand 2004;109:410-15.
27. Galli M, Luciani D, Bertolini G, et al. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 2003;101:1827-32.
28. Nash MJ, Camilleri RS, Kunka S, et al. The anticardiolipin assay is required for sensitive screening for antiphospholipid antibodies. J Thromb Haemost 2004;2:1077-81.
29. Rubenstein E, Arkfeld DG, Metyas S, et al. Rituximab treatment for resistant antiphospholipid syndrome. J Rheumatol 2006;33:355-7.
30. Furlan M, Robles R, Galbusera M, et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998;339:1578-84.
31. Girolami B, Prandoni P, Stefani PM, et al. The incidence of heparin-induced thrombocytopenia in hospitalized medical patients treated with subcutaneous unfractionated heparin: a prospective cohort study. Blood 2003;101:2955-9.
32. Keeling D, Davidson S, Watson H. The management of heparin-induced thrombocytopenia. Br J Haematol 2006;133:259-69.
33. Frenetic PS. Sickle cell vaso-occlusion: multistep and multicellular paradigm. Curr Opin Hematol 2002;9:101-6.
34. Ataga Ki, Orringer EP. Hypercoagulability in sickle cell disease: a curious paradox. Am J Med 2003;115:721-8.
35. Ohene-Frempong K, Weiner SJ, Sleeper LA, et al. Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood 1998;91:288-94.
36. Manci EA, Culberson DE, Yang YM, et al. Causes of death in sickle cell disease: an autopsy study. Br J Haematol 2003;123:359- 65.
37. Steinberg MH. Management of sickle cell disease. N Engl J Med 1999;340:1021-30.
38. Adams RJ, Brambilla DJ, Granger S, et al. Stroke and conversion to high risk in children screened with transcranial Doppler ultrasound during the STOP study. Blood 2004;103:3689-94.
39. Zimmerman SA, Schultz WH, Davis JS, et al. Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. Blood 2004;103:2039-45.
40. Hodden RD, Nobile-Orazio E, Sommer C, et al. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of paraproteinaemic demyelinating neuropathies: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. Eur J Neurol 2006;13:809-18.
41. Pepys MB. Amyloidosis. Annu Rev Med 2006;57:223-41.
42. Ferri C, Zignego AL, Pileri SA. Cryoglobulins. J Clin Pathol 2002;55:4-13.
43. Kuwabara S, Misawa S, Kanai K, et al. Autologous peripheral blood stem cell transplantation for POEMS syndrome. Neurology 2006;66:105-7.
44. Kyle RA, Therneau TM, Rajkumar SV, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 2002;346:564-9.
45. Dhodapkar MV, Jacobson JL, Gertz MA, et al. Prognostic factors and response to fludarabine therapy in Waldenstrom's macroglobulinemia: an update of a US intergroup trial (SW0G S9003). Semin Oncol 2003;30:220-5.
46. Tournilhac O, Leblond V, Tabrizi R, et al. Transplantation in Waldenstrom's macroglobulinemia - the French experience. Semin Oncol 2003;30:291-6.
47. Dimopoulos MA, Alexanian R, Gika D, et al. Treatment of Waldenstrom's macroglobulinemia with rituximab: prognostic factors for response and progression. Leuk Lymphoma 2004;45:2057-61.